Patents Assigned to Mercator Medsystems, Inc.
  • Patent number: 11813249
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: November 14, 2023
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 10576063
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 3, 2020
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 10441747
    Abstract: Methods and kits for delivering pharmaceutical agents to an adventitia and other regions outside an external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of a pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent. In one example, catheters are used to deliver dexamethasone and other anti-inflammatory agents to a peripheral vasculature and other vasculature to treat peripheral vascular disease and other conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 15, 2019
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 9884013
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 6, 2018
    Assignees: Abraxis BioScience, LLC, Mercator MedSystems, Inc.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 9789276
    Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: October 17, 2017
    Assignee: Mercator Medsystems, Inc.
    Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
  • Patent number: 9199065
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: December 1, 2015
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 9149497
    Abstract: Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: October 6, 2015
    Assignee: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Robert Cafferata
  • Patent number: 9011879
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: April 21, 2015
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Publication number: 20140303569
    Abstract: Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 9, 2014
    Applicant: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick SEWARD, Lynn Mateel BARR, Judith Carol WILBER, Robert CAFFERATA
  • Publication number: 20140296279
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 2, 2014
    Applicants: Mercator MedSystems, Inc., Abraxis BioScience, LLC
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 8721590
    Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: May 13, 2014
    Assignee: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
  • Patent number: 8708995
    Abstract: Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: April 29, 2014
    Assignee: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Judith Carol Wilber, Robert Cafferata
  • Publication number: 20140107478
    Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.
    Type: Application
    Filed: October 25, 2013
    Publication date: April 17, 2014
    Applicant: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick SEWARD, Isidro M. GANDIONCO, David GANDIONCO
  • Patent number: 8465752
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: June 18, 2013
    Assignee: Mercator Medsystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 8399443
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: March 19, 2013
    Assignee: Mercator Medsystems, Inc.
    Inventor: Kirk Patrick Seward
  • Publication number: 20110313353
    Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 22, 2011
    Applicant: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
  • Patent number: 8016786
    Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: September 13, 2011
    Assignee: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
  • Publication number: 20110104061
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Application
    Filed: April 22, 2010
    Publication date: May 5, 2011
    Applicant: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Publication number: 20110104060
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Application
    Filed: April 22, 2010
    Publication date: May 5, 2011
    Applicant: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Publication number: 20100305546
    Abstract: Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 2, 2010
    Applicant: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Judith Carol Wilber, Robert Cafferata